Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18925016 | 0.79 | ALDH1A1 (0.40) | LMNAALDH1A1MIF | |
| SCHEMBL7713805 | 0.77 | HTT (0.32) | — | |
| SCHEMBL10249594 | 0.77 | — | — | |
| SCHEMBL7905388 | 0.76 | MIF (0.33) | LMNAALDH1A1MIF | |
| SCHEMBL697173 | 0.76 | LMNA (0.37) | LMNAALDH1A1MIF | |
| SCHEMBL16019092 | 0.76 | LMNA (0.32) | LMNAALDH1A1MIF | |
| SCHEMBL15694063 | 0.75 | DGKA (0.39) | LMNAALDH1A1MIF | |
| SCHEMBL7878408 | 0.74 | DGAT1 (0.33) | ALDH1A1 | |
| SCHEMBL390512 | 0.74 | PRKCA (0.39) | ALDH1A1 | |
| SCHEMBL22958830 | 0.74 | BTN3A1 (0.34) | LMNAALDH1A1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101590-B2 | 9-aminocarbonylsubstituted derivatives of glycylcyclines | WYETH LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101590-B2 | 9-aminocarbonylsubstituted derivatives of glycylcyclines | WYETH LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101590-B2 | 9-aminocarbonylsubstituted derivatives of glycylcyclines | WYETH LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1919879-A1 | 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES | Wyeth a Corporation of the State of Delaware (US) | 2008-05-14 | — | — | EP | disclosed |
| US-7265140-B2 | Acyloxymethylcarbamate prodrugs of oxazolidinones | PFIZER INC (US) | 2007-09-04 | — | — | US | disclosed |
| WO-2007027599-A1 | 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES | WYETH (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027599-A1 | 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES | WYETH (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| EP-1668005-B1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1668005-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | Pharmacia & Upjohn Company LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | PHARMACIA & UPJOHN COMPANY LLC | 2005-12-01 | — | — | US | disclosed |
| WO-2005028473-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | HDAC3, HDAC1, OGA | LMNA 4674/4885ALDH1A1 591/4885MIF 1118/4885 |
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | Q6ZSR9, GMPS, RPS10 | LMNA 2954/4885ALDH1A1 1826/4885MIF 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.